Lagerstandorte

New Jersey, USA
Czech Republic, EU
Mumbai, India

* Vorbehaltlich Verfügbarkeit

Dokumentation

MSDS herunterladen

Beispiel-COA herunterladen

Enthält: HPLC, MASS/LC-MS, 1H-NMR, FT-IR, Gehalt, Structure Elucidation Report (SER) sowie zusätzliche analytische Daten je nach Produkt.

534-47-4Neomycin Sulfate EP Impurity D

● Under Development

Katalog-Nr.::	VE006930
CAS-Nr.::	534-47-4
Summenformel::	C12H25N3O7
Molare Masse::	323.35 g/mol

Wie können wir helfen?

Zur RFQ-Liste hinzufügen

Zusätzliche Informationen zu CAS 534-47-4

Parent drug

Neomycin

IUPAC-Name

4-O-(2-amino-2-deoxy-Î±-d-glucopyranosyl)-2-deoxy-d-streptamine

Pharmakopöe-Synonyme

Paromamine; Neomycin D

Other Synonyms

(2R,3S,4R,5R,6S)-5-amino-6-(((1R,2R,3S,4R,6S)-4,6-diamino-2,3-dihydroxycyclohexyl)oxy)-2-(hydroxymethyl)tetrahydro-2H-pyran-3,4-diol

InChI

InChI=1S/C12H25N3O7/c13-3-1-4(14)11(10(20)7(3)17)22-12-6(15)9(19)8(18)5(2-16)21-12/h3-12,16-20H,1-2,13-15H2/t3-,4+,5-,6-,7+,8-,9-,10-,11-,12-/m1/s1

SMILES

OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O)[C@H]2O)O1

Beschreibung

Neomycin Sulfate EP Impurity D, also known as Paromamine; Neomycin D in various pharmacopoeias, is a highly characterized standard. It meets strict regulatory requirements set by USP, EMA, JP, and BP, making it a crucial component in Abbreviated New Drug Applications (ANDA), New Drug Applications (NDA), and the commercial production of Neomycin. It is an impurity present in Neomycin which is produced by a species of Streptomyces fradiae present in the soil, is relatively thermostable, and is active against numerous gram-positive and gram-negative organisms.

References

Clarot, I., et al. â€œAnalysis of Neomycin Sulfate and Framycetin Sulfate by High-Performance Liquid Chromatography Using Evaporative Light Scattering Detection.â€ Journal of Chromatography A, vol. 1087, no. 1-2, Sept. 2005, pp. 236â€“44, https://doi.org/10.1016/j.chroma.2005.05.054.?Duncan, Garfield G. â€œNEOMYCIN: RESULTS of CLINICAL USE in TEN CASES.â€ Journal of the American Medical Association, vol. 145, no. 2, Jan. 1951, p. 75, https://doi.org/10.1001/jama.1951.02920200015005.?